{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T08:28:06Z","timestamp":1778228886417,"version":"3.51.4"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,5,24]]},"DOI":"10.7759\/cureus.84759","type":"journal-article","created":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T03:32:21Z","timestamp":1748143941000},"source":"Crossref","is-referenced-by-count":2,"title":["Wild-Type Transthyretin Amyloid Depositions in the Subcutaneous Fat and Skeletal Muscles of a Nonagenarian Who Had Heart Failure With Preserved Ejection Fraction and No Myocardial Technetium-99m-Labeled Pyrophosphate Uptake"],"prefix":"10.7759","author":[{"given":"Koji","family":"Takahashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitsuharu","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuji","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab072","article-title":"Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases","volume":"42","author":"Garcia-Pavia P","year":"2021","unstructured":"Garcia-Pavia P, Rapezzi C, Adler Y, et al.. Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2021, 42:1554-68. 10.1093\/eurheartj\/ehab072","journal-title":"Eur Heart J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-025-03547-0","article-title":"Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review","volume":"20","author":"Delgado D","year":"2025","unstructured":"Delgado D, Dabbous F, Shivappa N, Mazhar F, Wittbrodt E, Shridharmurthy D, J\u00e4rbrink K. Epidemiology of transthyretin (ATTR) amyloidosis: a systematic literature review. Orphanet J Rare Dis. 2025, 20:29. 10.1186\/s13023-025-03547-0","journal-title":"Orphanet J Rare Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2024.2405948","article-title":"Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee","volume":"31","author":"Buxbaum JN","year":"2024","unstructured":"Buxbaum JN, Eisenberg DS, F\u00e4ndrich M, et al.. Amyloid nomenclature 2024: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee. Amyloid. 2024, 31:249-56. 10.1080\/13506129.2024.2405948","journal-title":"Amyloid"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0442","article-title":"Cardiac amyloidosis due to transthyretin protein: a review","volume":"331","author":"Ruberg FL","year":"2024","unstructured":"Ruberg FL, Maurer MS. Cardiac amyloidosis due to transthyretin protein: a review. JAMA. 2024, 331:778-91. 10.1001\/jama.2024.0442","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehae811","article-title":"Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine","volume":"46","author":"Gonzalez-Lopez E","year":"2025","unstructured":"Gonzalez-Lopez E, Maurer MS, Garcia-Pavia P. Transthyretin amyloid cardiomyopathy: a paradigm for advancing precision medicine. Eur Heart J. 2025, 46:999-1013. 10.1093\/eurheartj\/ehae811","journal-title":"Eur Heart J"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2646","article-title":"Sex differences among patients with transthyretin amyloid cardiomyopathy\u00a0-\u00a0from diagnosis to prognosis","volume":"24","author":"Patel RK","year":"2022","unstructured":"Patel RK, Ioannou A, Razvi Y, et al.. Sex differences among patients with transthyretin amyloid cardiomyopathy\u00a0-\u00a0from diagnosis to prognosis. Eur J Heart Fail. 2022, 24:2355-63. 10.1002\/ejhf.2646","journal-title":"Eur J Heart Fail"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.119.006075","article-title":"Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis","volume":"12","author":"Maurer MS","year":"2019","unstructured":"Maurer MS, Bokhari S, Damy T, et al.. Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis. Circ Heart Fail. 2019, 12:e006075. 10.1161\/CIRCHEARTFAILURE.119.006075","journal-title":"Circ Heart Fail"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14220","article-title":"Multimodality assessments of wild-type transthyretin cardiac amyloidosis with no ventricular hypertrophy","volume":"10","author":"Iwaya T","year":"2023","unstructured":"Iwaya T, Okada A, Tateishi E, Ohta Y, Morita Y, Ohta-Ogo K, Izumi C. Multimodality assessments of wild-type transthyretin cardiac amyloidosis with no ventricular hypertrophy. ESC Heart Fail. 2023, 10:1412-7. 10.1002\/ehf2.14220","journal-title":"ESC Heart Fail"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-018-01552-4","article-title":"State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis","volume":"26","author":"Singh V","year":"2019","unstructured":"Singh V, Falk R, Di Carli MF, Kijewski M, Rapezzi C, Dorbala S. State-of-the-art radionuclide imaging in cardiac transthyretin amyloidosis. J Nucl Cardiol. 2019, 26:158-73. 10.1007\/s12350-018-01552-4","journal-title":"J Nucl Cardiol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/ehjci\/jeu107","article-title":"Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis","volume":"15","author":"Hutt DF","year":"2014","unstructured":"Hutt DF, Quigley AM, Page J, et al.. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis. Eur Heart J Cardiovasc Imaging. 2014, 15:1289-98. 10.1093\/ehjci\/jeu107","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-021-02890-6","article-title":"Amyloid deposit corresponds to technetium-99m-pyrophosphate accumulation in abdominal fat of patients with transthyretin cardiac amyloidosis","volume":"29","author":"Takahashi K","year":"2022","unstructured":"Takahashi K, Sasaki D, Yamashita M, et al.. Amyloid deposit corresponds to technetium-99m-pyrophosphate accumulation in abdominal fat of patients with transthyretin cardiac amyloidosis. J Nucl Cardiol. 2022, 29:3126-36. 10.1007\/s12350-021-02890-6","journal-title":"J Nucl Cardiol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000004397","article-title":"99mTc-pyrophosphate scintigraphy can image tracer uptake in skeletal trunk muscles of transthyretin cardiac amyloidosis","volume":"48","author":"Takahashi K","year":"2023","unstructured":"Takahashi K, Hiratsuka Y, Sasaki D, et al.. 99mTc-pyrophosphate scintigraphy can image tracer uptake in skeletal trunk muscles of transthyretin cardiac amyloidosis. Clin Nucl Med. 2023, 48:18-24. 10.1097\/RLU.0000000000004397","journal-title":"Clin Nucl Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1053\/j.semnuclmed.2009.07.003","article-title":"Patterns, variants, artifacts, and pitfalls in conventional radionuclide bone imaging and SPECT\/CT","volume":"39","author":"Gnanasegaran G","year":"2009","unstructured":"Gnanasegaran G, Cook G, Adamson K, Fogelman I. Patterns, variants, artifacts, and pitfalls in conventional radionuclide bone imaging and SPECT\/CT. Semin Nucl Med. 2009, 39:380-95. 10.1053\/j.semnuclmed.2009.07.003","journal-title":"Semin Nucl Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s12350-022-03128-9","article-title":"Two autopsy cases of wild-type transthyretin cardiac amyloidosis who died 10\u00a0days after technetium-99m-pyrophosphate scintigraphy","volume":"30","author":"Takahashi K","year":"2023","unstructured":"Takahashi K, Morioka H, Sasaki D, et al.. Two autopsy cases of wild-type transthyretin cardiac amyloidosis who died 10\u00a0days after technetium-99m-pyrophosphate scintigraphy. J Nucl Cardiol. 2023, 30:2215-21. 10.1007\/s12350-022-03128-9","journal-title":"J Nucl Cardiol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2023.2235881","article-title":"Technetium-99m-pyrophosphate imaging-based computed tomography-guided core-needle biopsy of internal oblique muscle in wild-type transthyretin cardiac amyloidosis","volume":"31","author":"Takahashi K","year":"2024","unstructured":"Takahashi K, Hiratsuka Y, Iwamura T, et al.. Technetium-99m-pyrophosphate imaging-based computed tomography-guided core-needle biopsy of internal oblique muscle in wild-type transthyretin cardiac amyloidosis. Amyloid. 2024, 31:12-21. 10.1080\/13506129.2023.2235881","journal-title":"Amyloid"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005521","article-title":"Wild-type transthyretin amyloidosis with 99mTc-PYP uptake in the extracardiac soft tissues but not in the myocardium","volume":"49","author":"Takahashi K","year":"2024","unstructured":"Takahashi K, Iwamura T, Sasaki D, Ueda M, Okura T. Wild-type transthyretin amyloidosis with 99mTc-PYP uptake in the extracardiac soft tissues but not in the myocardium. Clin Nucl Med. 2024, 49:1136-8. 10.1097\/RLU.0000000000005521","journal-title":"Clin Nucl Med"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.3389\/fcvm.2023.1151803","article-title":"Risk stratification in transthyretin-related cardiac amyloidosis","volume":"10","author":"Scirpa R","year":"2023","unstructured":"Scirpa R, Cittadini E, Mazzocchi L, et al.. Risk stratification in transthyretin-related cardiac amyloidosis. Front Cardiovasc Med. 2023, 10:1151803. 10.3389\/fcvm.2023.1151803","journal-title":"Front Cardiovasc Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1161\/HCI.0000000000000029","article-title":"ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging","volume":"14","author":"Dorbala S","year":"2021","unstructured":"Dorbala S, Ando Y, Bokhari S, et al.. ASNC\/AHA\/ASE\/EANM\/HFSA\/ISA\/SCMR\/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2-evidence base and standardized methods of imaging. Circ Cardiovasc Imaging. 2021, 14:e000029. 10.1161\/HCI.0000000000000029","journal-title":"Circ Cardiovasc Imaging"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac259","article-title":"Characteristics and natural history of early-stage cardiac transthyretin amyloidosis","volume":"43","author":"Law S","year":"2022","unstructured":"Law S, Bezard M, Petrie A, et al.. Characteristics and natural history of early-stage cardiac transthyretin amyloidosis. Eur Heart J. 2022, 43:2622-32. 10.1093\/eurheartj\/ehac259","journal-title":"Eur Heart J"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2022.07.007","article-title":"Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms","volume":"4","author":"Gonzalez-Lopez E","year":"2022","unstructured":"Gonzalez-Lopez E, Escobar-Lopez L, Obici L, et al.. Prognosis of transthyretin cardiac amyloidosis without heart failure symptoms. JACC CardioOncol. 2022, 4:442-54. 10.1016\/j.jaccao.2022.07.007","journal-title":"JACC CardioOncol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052256","article-title":"Trends in prevalence and outcome of heart failure with preserved ejection fraction","volume":"355","author":"Owan TE","year":"2006","unstructured":"Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006, 355:251-9. 10.1056\/NEJMoa052256","journal-title":"N Engl J Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1253\/circj.CJ-20-0110","article-title":"JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis","volume":"84","author":"Kitaoka H","year":"2020","unstructured":"Kitaoka H, Izumi C, Izumiya Y, et al.. JCS 2020 guideline on diagnosis and treatment of cardiac amyloidosis. Circ J. 2020, 84:1610-71. 10.1253\/circj.CJ-20-0110","journal-title":"Circ J"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-024-06865-w","article-title":"[(99m)Tc]Tc-hydroxydiphosphonate uptake in soft tissue is associated with amyloid load in subcutaneous abdominal fat tissue and mortality in wild-type transthyretin amyloidosis patients","volume":"52","author":"Tingen HS","year":"2024","unstructured":"Tingen HS, Groothof D, Tubben A, et al.. [(99m)Tc]Tc-hydroxydiphosphonate uptake in soft tissue is associated with amyloid load in subcutaneous abdominal fat tissue and mortality in wild-type transthyretin amyloidosis patients. Eur J Nucl Med Mol Imaging. 2024, 52:88-97. 10.1007\/s00259-024-06865-w","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.2198","article-title":"Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy","volume":"23","author":"Garcia-Pavia P","year":"2021","unstructured":"Garcia-Pavia P, Bengel F, Brito D, et al.. Expert consensus on the monitoring of transthyretin amyloid cardiomyopathy. Eur J Heart Fail. 2021, 23:895-905. 10.1002\/ejhf.2198","journal-title":"Eur J Heart Fail"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/368941-wild-type-transthyretin-amyloid-depositions-in-the-subcutaneous-fat-and-skeletal-muscles-of-a-nonagenarian-who-had-heart-failure-with-preserved-ejection-fraction-and-no-myocardial-technetium-99m-labeled-pyrophosphate-uptake","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,25]],"date-time":"2025-05-25T03:32:22Z","timestamp":1748143942000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/368941-wild-type-transthyretin-amyloid-depositions-in-the-subcutaneous-fat-and-skeletal-muscles-of-a-nonagenarian-who-had-heart-failure-with-preserved-ejection-fraction-and-no-myocardial-technetium-99m-labeled-pyrophosphate-uptake"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,24]]},"references-count":24,"URL":"https:\/\/doi.org\/10.7759\/cureus.84759","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5,24]]}}}